Rifaximin in Patients With Gastroesophageal Variceal Bleeding (NCT02991612) | Clinical Trial Compass
CompletedNot Applicable
Rifaximin in Patients With Gastroesophageal Variceal Bleeding
China80 participantsStarted 2016-11-25
Plain-language summary
The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18 y.o. ≤age≤75 y.o.;
* Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric N- butyl-cyanoacrylate injection).
Exclusion Criteria:
* age \<18 y.o. or age \> 75 y.o.;
* Never had the variceal bleeding episode before;
* Do not have endoscopic treatment;
* Combined with other malignant tumors (not exclude patients with hepatocellular carcinoma who don't need treatment at the moment);
* Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)
* Massive ascites or combined with other high-risk factors that require prophylaxis use of antibiotics.
* Acute variceal bleeding within 5 days.
* Refuse to participate